NEWS
Forte Biosciences, Inc. Announces Oversubscribed $53 Million Private Placement From Leading Healthcare Institutional Investors to Advance FB102 Across Autoimmune Indications
Forte Biosciences (NASDAQ: FBRX) has secured an oversubscribed $53 million private placement from leading healthcare institutional investors, including OrbiMed, Janus Henderson Investors, and Tybourne Capital Management. The funding will support the clinical advancement of FB102 across autoimmune indications. The company has completed its healthy volunteer study and is currently conducting a celiac disease trial with topline results expected in Q2 2025. Forte plans to expand FB102 development into additional indications over the next 12 months.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2538Followers
107Following
28KVisitors
Follow